Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study

Sunday, April 13, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-323, an innovative oral RSV L-Protein inhibitor, has demonstrated effectiveness in reducing disease severity and accelerating viral clearance during a human viral challenge study. This first-in-class treatment offers new hope for managing respiratory syncytial virus infections. The results suggest a significant advancement in therapeutic options for RSV.
Price reaction · baseline $4.69 (2025-04-11 close) · clean, no other ENTA news in the window
day 0 close
+5.1%
day 1 · peak
+9.8%
day 3
+8.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-323 shows promise as a first-in-class oral RSV L-Protein inhibitor.
  • The treatment significantly reduces disease severity in patients.
  • Accelerates viral clearance in a human viral challenge study.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-323?

EDP-323 is a first-in-class oral RSV L-Protein inhibitor designed to treat respiratory syncytial virus.

How does EDP-323 affect disease severity?

EDP-323 significantly reduces disease severity in patients with RSV.

What were the study results for EDP-323?

The study showed that EDP-323 accelerates viral clearance during a human viral challenge.

Is EDP-323 approved for use?

The article does not specify if EDP-323 is currently approved for use.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-323 RSV respiratory syncytial virus viral clearance
Last updated: Apr 13, 2025

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →